uniQure QURE Contingent consideration fair value adjustments

Contingent consideration fair value adjustments at other companies

PTC TherapeuticsPTCT

——

Beam TherapeuticsBEAM

——

InsmedINSM

——

Segments

By segment

See full

Single Reportable-$1.34M-210%

Other financials

Income statement

See full

Revenue$3.6M+127%

Gross profit$3.3M+144%

Operating income-$45.7M-16.2%

Net income-$53.5M-22.7%

EPS (diluted)-$0.85-3.7%

Balance sheet

See full

Cash & equivalents$140.0M-35.6%

Total debt$63.3M-4.3%

Total equity$149.3M+343%

Total assets$778.7M+28.6%

Cash flow

See full

Operating cash flow-$38.2M+13.3%

CapEx$140.0K+11.1%

Free cash flow-$38.4M+13.2%

Valuation

See full

Market cap$3.09B+78.4%

Enterprise value$3.02B+124%

P/S170.9×+85.1×

Profitability

See full

Gross margin90.6%-2.9pp

Operating margin-1,059.7%+380pp

Net margin-1,154.4%+89.3pp

FCF margin-953.7%+169pp

Returns & leverage

See full

Return on equity-228.2%-11.6pp

Debt / equity0.4×-1.5×

Current ratio10.4×-1.6×

Where this comes from

Reported directly by uniQure in its filing.

Tagged under the XBRL concept us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1.

The official record: uniQure’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about uniQure's contingent consideration fair value adjustments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is uniQure's contingent consideration fair value adjustments?: uniQure (QURE) reported contingent consideration fair value adjustments of -$1.34M in Q1 2026.
How has uniQure's contingent consideration fair value adjustments changed year-over-year?: uniQure's contingent consideration fair value adjustments decreased by 210.0% year-over-year, from $1.22M to -$1.34M.